反応式
[CH2:1]([C:3]1[CH:15]=[C:14]([C:16]2[N:20]=[C:19]([C:21]3[CH:26]=[C:25]([CH3:27])[C:24]([CH2:28][CH:29]([CH3:31])[CH3:30])=[CH:23][N:22]=3)[O:18][N:17]=2)[CH:13]=[C:12]([CH3:32])[C:4]=1[O:5][CH2:6][C@@H:7]([OH:11])[CH2:8][NH:9]C)[CH3:2].[K+].[CH2:34]([S:36]([NH-])(=[O:38])=[O:37])[CH3:35]>CN(C=O)C>[CH2:1]([C:3]1[CH:15]=[C:14]([C:16]2[N:20]=[C:19]([C:21]3[CH:26]=[C:25]([CH3:27])[C:24]([CH2:28][CH:29]([CH3:30])[CH3:31])=[CH:23][N:22]=3)[O:18][N:17]=2)[CH:13]=[C:12]([CH3:32])[C:4]=1[O:5][CH2:6][C@@H:7]([OH:11])[CH2:8][NH:9][S:36]([CH2:34][CH3:35])(=[O:38])=[O:37])[CH3:2]参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
A solution of the epoxide intermediate of Example 57 (step a, 25 mg, 61 μmol) and ethanesulfonamide potassium salt (27 mg, 184 μmol) in DMF (2 mL) is stirred at 60° C. for 18 h. The solvent is removed in vacuo and the crude product is purified by prep. HPLC to give the title compound (8 mg) as a colourless oil; LC-MS: tR=1.07 min, [M+H]+=517.12.
後処理
- customThe solvent is removed in vacuo
- customthe crude product is purified by prep
出典と根拠
- ORDレコード
- ord-802634dd8cf04804a5038a1714dbcfb3
- 出典データセット
- uspto-grants-2013_11
- 特許番号
- US08575200B2
関連ノート
読み込み中…